Global pharmaceutical value chain in the new world order

Switzerland and Basel in particular have a very strong pharmaceutical and biotech industry. Tens of thousands of jobs, a major part of the economy, countless investments as well as R&D activities in both public and private sector are dependent on it.

- What impact will the new world order have on the global pharmaceutical value chain?- What is the best strategy for global pharmaceutical companies in this new world order and what role should governments play?
- What shifts will we be seeing in the global value chain? What scenarios exist?
- What does this mean for the US, EU and Switzerland in particular?
- What is the best strategy for nations like Switzerland in this new world order?
- Switzerland has built up a successful and vibrant start-up ecosystem, particularly in bio-tech, over the last 15 years. What impact will these tectonic shifts have on biotech startups? How should they react? How can governments best support biotechs under these changing framework conditions?

Welcome speech
-   Conradin Cramer, President of the Canton Basel-Stadt

Opening Keynote
-  Helene Budliger Artieda, State Secretary for Economic Affairs

Podium speakers
- Helene Budliger Artieda, State Secretary for Economic Affairs
- Kaspar Sutter, Councillor of the Canton of Basel-Stadt
- Severin Schwan, Chairman Roche
- Prof. Rolf Weder, International Economics, University of Basel 
- Dr. Xiaobin Wu, President & COO BeOne Medicines
- Srishti Gupta, CEO Idorsia

Moderation
- Olivia Kinghorst

Contact for event registration
Martin Stricker, Office of Economy and Labour, Canton of Basel-Stadt, martin.stricker@bs.ch

Contact for communication & media requests
Karin Sartorius, Office of Economy and Labour, Canton of Basel-Stadt, karin.sartorius@bs.ch